Citius Pharmaceuticals Enters Material Definitive Agreement

Ticker: CTXR · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1506251

Sentiment: neutral

Topics: material-definitive-agreement, corporate-event

TL;DR

CTRS inks new deal, big moves ahead.

AI Summary

Citius Pharmaceuticals, Inc. announced on April 1, 2025, that it has entered into a material definitive agreement. The company, incorporated in Nevada, is involved in the pharmaceutical preparations industry and is headquartered in Cranford, NJ.

Why It Matters

This filing indicates a significant new development for Citius Pharmaceuticals, potentially impacting its future operations and strategic direction.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Citius Pharmaceuticals?

The filing states that Citius Pharmaceuticals, Inc. entered into a material definitive agreement on April 1, 2025, but the specific details of this agreement are not provided in this 8-K filing.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on April 1, 2025.

In which state is Citius Pharmaceuticals, Inc. incorporated?

Citius Pharmaceuticals, Inc. is incorporated in Nevada.

What is the principal executive office address for Citius Pharmaceuticals, Inc.?

The principal executive offices of Citius Pharmaceuticals, Inc. are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

Has Citius Pharmaceuticals, Inc. had previous company names?

Yes, Citius Pharmaceuticals, Inc. was formerly known as Trail One, Inc., with name changes recorded on March 14, 2011, and November 19, 2010.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Citius Pharmaceuticals, Inc. (CTXR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing